Valuation: PolyNovo Limited

Market Cap 611M 413M 375M 346M 313M 591M 38.76B 4.17B 1.65B 20.8B 1.55B 1.52B 65.88B P/E 2027 *
62.8x
P/E 2028 * 33.1x
Enterprise Value 571M 386M 350M 324M 292M 552M 36.22B 3.89B 1.54B 19.44B 1.45B 1.42B 61.57B EV / Sales 2027 *
3.53x
EV / Sales 2028 * 2.99x
Free-Float
90.03%
Yield 2027 *
-
Yield 2028 * -
1 day-1.69%
1 week-1.69%
Current month-3.87%
1 month-5.43%
3 months-13.86%
6 months-17.92%
Current year-29.27%
1 week 0.86
Extreme 0.865
0.92
1 month 0.84
Extreme 0.84
0.94
Current year 0.81
Extreme 0.81
1.3
1 year 0.81
Extreme 0.81
1.3
3 years 0.81
Extreme 0.81
2.78
5 years 0.81
Extreme 0.81
2.78
10 years 0.17
Extreme 0.17
4.08
Manager TitleAgeSince
Chief Executive Officer - 01/12/2025
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman - 27/10/2025
Director/Board Member 48 04/06/2021
Director/Board Member 66 14/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
16/03/26 Buy

Director

151,000 0.0219%
27/02/26 Buy

Director

100,000 0.0145%
27/02/26 Buy

Chairman

30,000 0.0043%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%-1.69%-25.64%-37.18% 413M
-0.99%-2.77%-17.72%+7.17% 186B
+0.02%+0.09%+7.31%+37.39% 126B
+0.35%-4.61%-14.22%+6.58% 118B
+1.18%-3.20%-42.14%+3.72% 93.33B
-0.58%+3.23%-1.38%+81.27% 68.11B
-0.72%+0.57%+12.14%-7.91% 58.96B
-0.51%-0.85%+1.55%+50.15% 55.2B
-0.45%-1.00%-2.68%+37.47% 48.58B
+1.27%+1.50%+0.71%-0.19% 35.56B
Average -0.21%-0.35%-8.21%+17.85% 79B
Weighted average by Cap. -0.15%-0.95%-9.36%+21.26%

Financials

2027 *2028 *
Net sales 162M 109M 99.23M 91.68M 82.81M 156M 10.26B 1.1B 437M 5.5B 410M 401M 17.43B 186M 125M 114M 105M 95.05M 179M 11.77B 1.27B 501M 6.32B 470M 460M 20.01B
Net income 9.77M 6.6M 5.99M 5.54M 5M 9.44M 620M 66.6M 26.39M 332M 24.76M 24.23M 1.05B 18.5M 12.49M 11.35M 10.48M 9.47M 17.87M 1.17B 126M 49.95M 629M 46.86M 45.87M 1.99B
Net Debt -40.06M -27.04M -24.57M -22.7M -20.5M -38.69M -2.54B -273M -108M -1.36B -101M -99.33M -4.32B -55.32M -37.35M -33.93M -31.35M -28.32M -53.44M -3.51B -377M -149M -1.88B -140M -137M -5.96B
Projected Income Statement - Annual - PolyNovo Limited
Logo PolyNovo Limited
PolyNovo Limited is an Australia-based medical technology company. The Company’s business includes designing, manufacturing and selling biomedical devices. Its principal activity is the development of medical devices for medical applications, utilizing the patented bioabsorbable polymer technology NovoSorb. NovoSorb is a family of proprietary medical grade polymers that can be utilized to manufacture medical devices designed to support tissue repair. NovoSorb polymer devices can be expressed in a variety of physical formats including foam, coatings, fibers, plastic structures, films, and biologic carriers. Its products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a bilayer dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb MTX has applicability for single stage grafting in burns, chronic, and surgical wounds.
Employees
301
Date Price Change Volume
17/11/26 A$0.8700 -1.69% 366,138
16/11/26 A$0.8850 0.00% 452,618
13/11/26 A$0.8850 -1.12% 833,799
12/11/26 A$0.8950 -1.10% 536,234
11/11/26 A$0.9050 +2.26% 640,882
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - PolyNovo Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8850AUD
Average target price
1.254AUD
Spread / Average Target
+41.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyNovo Limited